Literature DB >> 28071585

Newborn Bilirubin Screening for Preventing Severe Hyperbilirubinemia and Bilirubin Encephalopathy: A Rapid Review.

Kalpana Bhardwaj1, Tiffany Locke1, Anne Biringer2, Allyson Booth3, Elizabeth K Darling4, Shelley Dougan1, Jane Harrison5, Stephen Hill6, Ana Johnson7, Susan Makin8, Beth Potter9, Thierry Lacaze-Masmonteil1, Julian Little9.   

Abstract

According to the 2004 American Academy of Pediatrics guideline on the management of hyperbilirubinemia, every newborn should be assessed for the risk of developing severe hyperbilirubinemia with the help of predischarge total serum bilirubin or transcutaneous bilirubin measurements and/or assessments of clinical risk factors. The aim of this rapid review is 1) to review the evidence for 1) predicting and preventing severe hyperbilirubinemia and bilirubin encephalopathy, 2) determining the efficacy of home/community treatments (home phototherapy) in the prevention of severe hyperbilirubinemia, and 3) non-invasive/transcutaneous methods for estimating serum bilirubin level.
METHODS: In this rapid review, studies were identified through the Medline database. The main outcomes of interest were severe hyperbilirubinemia and encephalopathy. A subset of articles was double screened and all articles were critically appraised using the SIGN and AMSTAR checklists. This review investigated if systems approach is likely to reduce the occurrence of severe hyperbilirubinemia.
RESULTS: Fifty-two studies met the inclusion criteria. Included studies assessed the association between bilirubin measurement early in neonatal life and the subsequent development of severe hyperbilirubinemia and chronic bilirubin encephalopathy/kernicterus. It was observed that, highest priority should be given to (i) universal bilirubin screening programs; (ii) implementation of community and midwife practice; (iii) outreach to communities for education of prospective parents; and (iv) development of clinical pathways to monitor, evaluate and track infants with severe hyperbilirubinemia.
CONCLUSIONS: We found substantial observational evidence that severe hyperbilirubinemia can be accurately predicted and prevented through universal bilirubin screening. So far, there is no evidence of any harm. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Bilirubin encephalopathy; hyperbilirubinemia; neonatal screening; universal bilirubin screening

Mesh:

Substances:

Year:  2017        PMID: 28071585     DOI: 10.2174/1573396313666170110144345

Source DB:  PubMed          Journal:  Curr Pediatr Rev        ISSN: 1573-3963


  4 in total

1.  Early prediction of adverse outcomes in infants with acute bilirubin encephalopathy.

Authors:  Wenqing Kang; Xiao Yuan; Yaodong Zhang; Juan Song; Falin Xu; Dapeng Liu; Rui Li; Bangli Xu; Wen Li; Yanchao Cheng; Changlian Zhu
Journal:  Ann Clin Transl Neurol       Date:  2020-06-04       Impact factor: 4.511

2.  Screening and treatment to reduce severe hyperbilirubinaemia in infants in primary care (STARSHIP): a factorial stepped-wedge cluster randomised controlled trial protocol.

Authors:  Berthe A M van der Geest; Johanna P de Graaf; Loes C M Bertens; Marten J Poley; Erwin Ista; René F Kornelisse; Irwin K M Reiss; Eric A P Steegers; Jasper V Been
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

3.  Diagnostic Performance Analysis of the Point-of-Care Bilistick System in Identifying Severe Neonatal Hyperbilirubinemia by a Multi-Country Approach.

Authors:  Chiara Greco; Iman F Iskander; Salma Z El Houchi; Rinawati Rohsiswatmo; Lily Rundjan; Williams N Ogala; Akinyemi O D Ofakunrin; Luciano Moccia; Nguyen Thi Xuan Hoi; Giorgio Bedogni; Claudio Tiribelli; Carlos D Coda Zabetta
Journal:  EClinicalMedicine       Date:  2018-07-17

4.  Identification of Genetic Risk Factors for Neonatal Hyperbilirubinemia in Fujian Province, Southeastern China: A Case-Control Study.

Authors:  Jinfu Zhou; Changyi Yang; Wenbin Zhu; Shuwei Chen; Yinglin Zeng; Jing Wang; Hong Zhao; Yao Chen; Feng Lin
Journal:  Biomed Res Int       Date:  2018-09-12       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.